XTX Topco’s Tvardi Therapeutics TVRD Stock Holding History

XTX Topco’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.2K	Buy	+14,868	New	+$46.6K	﹤0.01%	3841
2026 Q1	–	Sell	-12,838	Closed	-$55.2K	–	4563
2025 Q4	$55.2K	Buy	+12,838	New	+$115K	﹤0.01%	2804
2024 Q4	–	Sell	-2,631	Closed	-$29.2K	–	3067
2024 Q3	$29.2K	Buy	+2,631	New	+$30.8K	﹤0.01%	1782
2024 Q2	–	Sell	-1,007	Closed	-$33K	–	2580
2024 Q1	$33K	Buy	1,007 +251	+33%	+$6.51K	﹤0.01%	1538
2023 Q4	$20.2K	Buy	756 +251	+50%	+$10.4K	﹤0.01%	1357
2023 Q3	$30.5K	Sell	505 -940	-65%	-$88.2K	0.01%	1335
2023 Q2	$147K	Sell	1,445 -1,544	-52%	-$213K	0.03%	1095
2023 Q1	$528K	Buy	2,989 +2,600	+668%	+$871K	0.11%	261
2022 Q4	$150K	Buy	+389	New	+$148K	0.03%	922

Other funds holding TVRD

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

XTX Topco's TVRD Position: Q2 2026 in Review

XTX Topco opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 14,868 shares worth $28.2K. The stake represents ﹤0.01% of the portfolio and ranks #3841 among its holdings. This is a return to the name: XTX Topco previously reported a position in TVRD as recently as Q4 2025.

XTX Topco first reported a position in TVRD in Q4 2022 and has held it in 9 quarters since. The position peaked at $528K in Q1 2023. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

XTX Topco held 14,868 shares of Tvardi Therapeutics worth $28.2K as of Q2 2026.
Tvardi Therapeutics was a new XTX Topco position in Q2 2026.
Tvardi Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3841 holding.
XTX Topco first reported a position in Tvardi Therapeutics in Q4 2022 and has held it in 9 quarters since.
XTX Topco's Tvardi Therapeutics position peaked at $528K in Q1 2023.
58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.